Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma
| Autor: | Matko Kalac, Markus Y. Mapara, Jennifer E Amengual, Ahmed Sawas, Ithamar Turenne, Jennifer K. Lue, Emily Lichtenstein, Celeste Rojas, Owen A. O'Connor, John Kuruvilla, Changchun Deng, Joseph M. Connors |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Bendamustine Oncology medicine.medical_specialty Antibody-drug conjugate Immunoconjugates medicine.drug_class medicine.medical_treatment Monoclonal antibody Young Adult 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Refractory Hodgkin Lymphoma Bendamustine Hydrochloride Humans In patient Brentuximab vedotin Complete response Brentuximab Vedotin Chemotherapy business.industry Hematology Middle Aged Hodgkin Disease Treatment Outcome 030220 oncology & carcinogenesis Female business 030215 immunology medicine.drug |
| Zdroj: | British Journal of Haematology. 180:757-760 |
| ISSN: | 0007-1048 |
| DOI: | 10.1111/bjh.14449 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text